Experimental evidence in vitro and in vivo identifies the role of the XCTA MAGEA3 in tumor progression through apoptosis inhibition by Survivin upregulation, which underscores the role of MAGEA3 as a novel therapeutic target in HCC. The gene discussed is MAGEA3; the disease is hepatocellular carcinoma.